On September 26 2021 the German population voted for a change in politics. In December 2021 the new government started their work including Prof. Dr. Karl Lauterbach as their new Ministry of Health. What does this change potentially mean to the pharmaceutical industry especially for market access? Initial actions have already been concluded in the coalition contract such as an increase of the mandatory drug rebate and the change in free pricing within the AMNOG process. Listen to the opinions of German experts Dr. Stefan Walzer and prof. Dr. Thomas Breisach.